Blue Matter Blog
October 27, 2021
At some point, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity. Europe is attractive and offers vast market potential. But successfully entering Europe is a complex undertaking. The stakes are high and there are many pitfalls to avoid. In this series of articles, we’re outlining the 12 …
October 20, 2021
At some point in its development, any growth-minded non-European biopharma company will look to Europe as a possible source of new opportunity. Europe is attractive for various reasons, including its large population, high per-capita spend on healthcare, and vast market potential. But successfully entering Europe is a complex undertaking, and biopharma companies need to know …
October 12, 2021
As we’ve written many times before, Europe offers significant business opportunities for biopharmaceutical companies seeking to expand. Collectively, European countries represent the world’s second largest market for branded pharmaceuticals, just behind the United States. With more than 500 million people and $140 billion in annual branded pharmaceutical sales, Europe can be highly attractive. It offers …